Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Juni 2022 - 2:00PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the “Company” or
“Viridian”), a biotechnology company advancing new treatments for
patients suffering from serious diseases underserved by current
therapies, today announced that a majority of the independent
directors serving on the Company’s Board of Directors approved the
grant of stock options to purchase, an aggregate of 266,000 shares
of the Company’s common stock, to five new employees (the
“Inducement Grants”) on June 1, 2022 (the “Grant Date”). The
Inducement Grants have been granted outside of the Company’s
Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but
remain subject to the terms and conditions of such Plan. The
Inducement Grants were granted as an inducement material to these
individuals entering into employment with Viridian in accordance
with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is
equal to the closing price of Viridian’s common stock on the Grant
Date. The Inducement Grants will vest over a four-year period, with
25% of the shares vesting on the one-year anniversary of the Grant
Date, and thereafter the remainder of the shares vest in 36 equal
monthly installments, subject to continued employment through the
applicable vesting dates.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing
new treatments for patients suffering from serious diseases but
underserved by today’s therapies. Viridian’s most advanced program,
VRDN-001, is a differentiated monoclonal antibody targeting
insulin-like growth factor-1 receptor (IGF-1R), a clinically and
commercially validated target for the treatment of thyroid eye
disease (TED). Viridian’s second product candidate, VRDN-002, is a
distinct anti-IGF-1R antibody that incorporates half-life extension
technology and is designed to support administration as a
convenient, low-volume, subcutaneous injection. TED is a
debilitating autoimmune disease that causes inflammation and
fibrosis within the orbit of the eye which can cause double vision,
pain, and potential blindness. Patients with severe disease often
require multiple remedial surgeries to the orbit, eye muscles and
eyelids. Viridian is based in Waltham, Massachusetts.
Investor and Media ContactJohn JordanViridian
TherapeuticsVice President, Investor Relations& Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024